Literature DB >> 8107219

A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.

L G Gürtler1, P H Hauser, J Eberle, A von Brunn, S Knapp, L Zekeng, J M Tsague, L Kaptue.   

Abstract

A new subtype (MVP-5180) of human immunodeficiency virus type 1 (HIV-1) was isolated from a Cameroonian AIDS patient. MVP-5180 was grown in several human T-cell lines and the monocytic U937 line. MVP-5180 DNA could not be amplified by nested primer PCR with conventional env primers and could be only very faintly amplified with gag and pol primers. Most German, Ivoirian, and Malawian anti-HIV-1 sera reacted faintly or moderately with Env proteins in an MVP-5180 immunoblot, whereas some Cameroonian sera reacted strongly. Of HIV-1-infected Cameroonians, 8% were identified by serological methods as infected with MVP-5180; 7% were positive when MVP-5180-specific PCR env primers were used. DNA sequence analysis of MVP-5180 showed that its genetic organization was that of HIV-1, with 65% similarity to HIV-1 and 56% similarity to HIV-2 consensus sequences. The env gene of MVP-5180 had similarities to HIV-1 and HIV-2 of 53 and of 49%, respectively. V3 loop analysis identified a crown of Gly-Pro-Met-Arg by using cloned DNA and Gly-Pro-Leu-Arg by using PCR-amplified DNA, neither of which configuration has been described for other HIV strains. In an analysis of relationships, MVP-5180 occupied a position distant to all other HIV-1 strains, including the chimpanzee simian immunodeficiency virus type 1 SIVcpz and the Uganda virus U455, and closer to the HIV-1/HIV-2 divergence node. MVP-5180, together with another Cameroonian isolate, ANT-70, constitutes a group subtype O of the most divergent HIV-1 isolates yet identified. Characterization of MVP-5180 is important for understanding the natural history of the primate immunodeficiency viruses and for the development of vaccines and diagnostics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107219      PMCID: PMC236615     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

2.  DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.

Authors:  C Y Ou; S Kwok; S W Mitchell; D H Mack; J J Sninsky; J W Krebs; P Feorino; D Warfield; G Schochetman
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

3.  Sensitivity and specificity of commercial ELISA kits for screening anti-LAV/HTLV III.

Authors:  L G Gürtler; J Eberle; B Lorbeer; F Deinhardt
Journal:  J Virol Methods       Date:  1987-01       Impact factor: 2.014

4.  Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates.

Authors:  M W Cloyd; B E Moore
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

5.  A highly divergent HIV-2-related isolate.

Authors:  U Dietrich; M Adamski; R Kreutz; A Seipp; H Kühnel; H Rübsamen-Waigmann
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

6.  Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon.

Authors:  M Peeters; C Honoré; T Huet; L Bedjabaga; S Ossari; P Bussi; R W Cooper; E Delaporte
Journal:  AIDS       Date:  1989-10       Impact factor: 4.177

7.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin.

Authors:  R De Leys; B Vanderborght; M Vanden Haesevelde; L Heyndrickx; A van Geel; C Wauters; R Bernaerts; E Saman; P Nijs; B Willems
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

View more
  74 in total

1.  The molecular population genetics of HIV-1 group O.

Authors:  Philippe Lemey; Oliver G Pybus; Andrew Rambaut; Alexei J Drummond; David L Robertson; Pierre Roques; Michael Worobey; Anne-Mieke Vandamme
Journal:  Genetics       Date:  2004-07       Impact factor: 4.562

2.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Development of a Versatile, Near Full Genome Amplification and Sequencing Approach for a Broad Variety of HIV-1 Group M Variants.

Authors:  Andrew N Banin; Michael Tuen; Jude S Bimela; Marcel Tongo; Paul Zappile; Alireza Khodadadi-Jamayran; Aubin J Nanfack; Josephine Meli; Xiaohong Wang; Dora Mbanya; Jeanne Ngogang; Adriana Heguy; Phillipe N Nyambi; Charles Fokunang; Ralf Duerr
Journal:  Viruses       Date:  2019-04-01       Impact factor: 5.048

4.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

6.  Integrating laboratory and epidemiological techniques for population-based surveillance of HIV strains and drug resistance in Canada.

Authors:  G C Jayaraman; C P Archibald; L Lior; D Sutherland
Journal:  Can J Infect Dis       Date:  2000-03

7.  Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid.

Authors:  Ryan Reinke; Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild.

Authors:  M J Jin; J Rogers; J E Phillips-Conroy; J S Allan; R C Desrosiers; G M Shaw; P M Sharp; B H Hahn
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.